SCHEMBL5524930

SCHEMBL5524930

COC(=O)C1(C)CCN(C)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SCN1A P35498 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
NPSR1 Q6W5P4 1/20 0.34
CYP3A4 P08684 3/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
OPRK1 P41145 3/20 0.31
OPRM1 P35372 2/20 0.31
SLC22A1 O15245 1/20 0.31
SLC6A4 P31645 1/20 0.31
ADRA1A P35348 1/20 0.31
OPRD1 P41143 1/20 0.31
KCNH2 Q12809 1/20 0.31
LMNA P02545 1/20 0.31
MMP1 P03956 1/20 0.31
MMP9 P14780 1/20 0.31
MMP13 P45452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163087 0.89 USP2 (0.50) USP2SCN1ASCN2ASCN3ANPSR1
SCHEMBL2055527 0.88 SCN1A (0.42) USP2SCN1ASCN2ASCN3ANPSR1
SCHEMBL16573819 0.83 OPRK1 (0.36) USP2SCN1ASCN2ASCN3ANPSR1
SCHEMBL23396157 0.79 CYP2D6 (0.38) USP2SCN1ASCN2ASCN3A
SCHEMBL18195617 0.79 CYP4F2 (0.37) USP2SCN1ASCN2ASCN3A
SCHEMBL1468595 0.77 USP2 (0.36) USP2NPSR1CYP3A4CYP2C19MEN1
SCHEMBL18169570 0.77 FFAR3 (0.50) USP2SCN1ASCN2ASCN3ACYP3A4
SCHEMBL25583798 0.77 CYP1A2 (0.34) USP2SCN1ASCN2ASCN3ACYP3A4
SCHEMBL29470957 0.77 OPRM1 (0.36) SCN1ASCN2ASCN3AOPRK1OPRM1
SCHEMBL24347023 0.76 USP2 (0.41) USP2SCN1ASCN2ASCN3ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4019506-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2022-06-29 EP disclosed
EP-3083579-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2022-01-26 EP disclosed
WO-2021000041-A1 IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY Precision Nanosystems Inc. (CA) 2021-01-07 WO disclosed
WO-2020081572-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-23 WO disclosed
WO-2015095346-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2015-06-25 WO disclosed
US-20070219210-A1 Amidopyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-20 US disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
US-5686463-A Oxadiazoles useful in the treatment of senile dementia MERCK, SHARP & DOHME, LTD. (GB) 1997-11-11 US disclosed
EP-0239309-B1 Oxadiazoles useful in the treatment of senile dementia MERCK SHARP & DOHME (GB) 1994-01-12 EP disclosed
EP-0239309-A2 Oxadiazoles useful in the treatment of senile dementia MERCK SHARP & DOHME LTD. (GB) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219210-A1 Amidopyrazole Derivative PTGER1, PTGS1, PTGER2 USP2 1171/4885SCN1A 1269/4885SCN2A 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.